A novel role for the major histocompatibility complex class II transactivator CIITA in the repression of IL-4 production.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

A novel role for the major histocompatibility complex class II transactivator CIITA in the repression of IL-4 production.

Immunity. 1999 Mar;10(3):377-86. Unique Identifier : AIDSLINE MED/99219187
Gourley T; Roys S; Lukacs NW; Kunkel SL; Flavell RA; Chang CH; Department of Microbiology and Immunology, University of Michigan; Medical School, Ann Arbor 48109, USA.

Abstract: Class II transactivator (CIITA) is known as a coactivator for MHC class II gene expression in antigen-presenting cells. Surprisingly, when CIITA-/- CD4 T cells were stimulated in the presence of IL-12, they produced not only IFNgamma but also high levels of IL-4. The IL-4 production is due to the accumulation of IL-4 gene transcripts in Th1 cells. This transcriptional control is observed in T cells differentiating to the Th1 but not Th2 lineage, consistent with induction of expression of the CIITA gene in T cells by IFNgamma. Thus, in addition to its role in transactivation of genes involved in antigen presentation, CIITA plays a critical role during the T cell differentiation by negatively regulating the IL-4 gene transcription.

Keywords: JOURNAL ARTICLE Animal CD4-Positive T-Lymphocytes/METABOLISM Down-Regulation (Physiology)/GENETICS/IMMUNOLOGY Gene Expression Regulation/IMMUNOLOGY Genes, MHC Class II/GENETICS/IMMUNOLOGY/*PHYSIOLOGY Granuloma, Respiratory Tract/IMMUNOLOGY/METABOLISM Histocompatibility Antigens Class II/BIOSYNTHESIS Interleukin-4/*ANTAGONISTS & INHIB/*BIOSYNTHESIS Mice Mice, Congenic Mice, Inbred C57BL Support, Non-U.S. Gov't Th1 Cells/METABOLISM Th2 Cells/METABOLISM Trans-Activators/DEFICIENCY/GENETICS/IMMUNOLOGY/*PHYSIOLOGY Transgenes/GENETICS/IMMUNOLOGY
990730
A9971190

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .